New York State Common Retirement Fund cut its position in Danaher Corporation (NYSE:DHR – Free Report) by 6.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 796,185 shares of the conglomerate’s stock after selling 50,500 shares during the quarter. New York State Common Retirement Fund’s holdings in Danaher were worth $157,852,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently made changes to their positions in the company. Sivia Capital Partners LLC raised its holdings in shares of Danaher by 6.3% in the 2nd quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after acquiring an additional 119 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Danaher by 7.7% in the second quarter. Janney Montgomery Scott LLC now owns 199,045 shares of the conglomerate’s stock worth $39,319,000 after purchasing an additional 14,277 shares during the last quarter. Capital Investment Advisors LLC raised its stake in Danaher by 1.2% in the second quarter. Capital Investment Advisors LLC now owns 7,352 shares of the conglomerate’s stock valued at $1,452,000 after purchasing an additional 85 shares in the last quarter. Trivium Point Advisory LLC lifted its position in Danaher by 35.4% during the second quarter. Trivium Point Advisory LLC now owns 2,242 shares of the conglomerate’s stock valued at $443,000 after purchasing an additional 586 shares during the last quarter. Finally, Liberty Capital Management Inc. grew its stake in Danaher by 3.3% in the 2nd quarter. Liberty Capital Management Inc. now owns 35,300 shares of the conglomerate’s stock worth $6,973,000 after buying an additional 1,128 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Danaher
In related news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Teri List sold 3,298 shares of Danaher stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the sale, the director owned 20,762 shares in the company, valued at approximately $4,702,593. This trade represents a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 30,248 shares of company stock valued at $6,609,663 in the last 90 days. Insiders own 11.20% of the company’s stock.
Danaher Price Performance
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, topping the consensus estimate of $2.14 by $0.09. The company had revenue of $6.84 billion for the quarter, compared to the consensus estimate of $6.79 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is presently 26.39%.
Key Headlines Impacting Danaher
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: Q4 results beat consensus: Danaher reported $2.23 EPS and revenue of $6.84B (y/y +4.5%), topping estimates and showing broad-based growth across segments. Danaher Reports Fourth Quarter and Full Year 2025 Results
- Positive Sentiment: Bioprocessing and diagnostics momentum and strong free cash flow were highlighted on the call, supporting operational quality and potential upside as pharma spending recovers. Danaher Corp (DHR) Q4 2025 Earnings Call Highlights
- Positive Sentiment: Analysts remain constructive: several firms reiterated Buy/outperform views, pointing to core performance and bioprocessing upside despite near-term headwinds. Danaher: Solid Core Performance and Bioprocessing Upside Support Buy Rating into 2026
- Neutral Sentiment: FY?2026 EPS guidance set to $8.35–$8.50, effectively in line with the Street (consensus ~8.42), so guidance neither materially beats nor misses expectations. Danaher forecasts 2026 profit line with estimates on pharma spending recovery
- Neutral Sentiment: Management tone: the company expects a gradual improvement in pharma and other end markets but signaled uneven recovery and some caution around academic research spending. Danaher Expects Gradual Improvement In End-Market Conditions
- Negative Sentiment: Market reaction: despite the beat, investors sold shares after the outlook and cautious commentary were viewed as merely in-line — weighing on the stock in premarket and intraday trading. Danaher stock drops after Q4 2025 results
Analyst Ratings Changes
DHR has been the topic of several research reports. TD Cowen restated a “buy” rating on shares of Danaher in a research report on Wednesday, January 7th. Redburn Partners set a $220.00 price target on Danaher in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price target on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Barclays increased their price objective on Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Morgan Stanley initiated coverage on Danaher in a research report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price for the company. Twenty research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $252.70.
Check Out Our Latest Analysis on Danaher
Danaher Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Stories
- Five stocks we like better than Danaher
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
